Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study

Tomasson, M. H., Iida, S., Niesvizky, R., Mohty, M., Bahlis, N. J., Martinez-Lopez, J., … Lesokhin, A. M. (2024, July 1). Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study. HemaSphere. John Wiley and Sons Inc. https://doi.org/10.1002/hem3.136